Business
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
HAYWARD, Calif., January 07, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases, today outlined its 2026 priorities for casdatifan and its emerging inflammation and immunology (I&I) programs.
About this update from Arcus Biosciences, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Arcus’s highest priority is to execute on its ongoing Phase 3 trial and overall development plan aimed at establishing casdatifan as the standard-of-care and backbone therapy for clear cell renal cell carcinoma (ccRCC), including the initiation of a Phase 3 trial in the first-line (1L) setting","length":294,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"At least three data presentations are planned for casdatifan in 2026, including updated data from the four late-line monotherapy cohorts of the Phase 1/1b ARC-20 study, which will be presented at a medical conference in February 2026","length":233,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Arcus’s first development candidate for inflammatory and autoimmune diseases, an oral MRGPRX2 antagonist for chronic spontaneous urticaria, is expected to enter the clinic in 2026","length":179,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"With approximately $1 billion of cash and investmentsi, Arcus expects to be able to fund its planned operations until at least the second half of 2028","length":150,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Arcus will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026","length":102,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":958,"olType":false},{"type":"text","content":"HAYWARD, Calif., January 07, 2026--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases, today outlined its 2026 priorities for casdatifan and its emerging inflammation and immunology (I&I) programs.","length":368,"tagName":"p"},{"type":"text","content":""As we enter 2026, the highest priorities for Arcus will be the rapid enrollment of PEAK-1, our Phase 3 study evaluating casdatifan in immunotherapy (IO)-experienced ccRCC patients, and the initiation of a 1L Phase 3 study evaluating casdatifan informed by data from multiple ongoing and soon-to-be initiated Phase 1 combination studies," said Terry Rosen, Ph.D., chief executive officer of Arcus. "This year, we also expect to advance our first small molecule for inflammatory disease int...